KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Receivables (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Change in Receivables for 12 consecutive years, with -$27.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 1502.17% year-over-year to -$27.8 million, compared with a TTM value of $27.8 million through Dec 2025, up 363.62%, and an annual FY2025 reading of $27.8 million, up 363.62% over the prior year.
  • Change in Receivables was -$27.8 million for Q4 2025 at Travere Therapeutics, down from $44.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $44.2 million in Q3 2025 and bottomed at -$27.8 million in Q4 2025.
  • Average Change in Receivables over 5 years is $2.3 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Change in Receivables tumbled 4773.77% in 2021, then surged 5940.36% in 2025.
  • Year by year, Change in Receivables stood at $1.7 million in 2021, then skyrocketed by 248.26% to $6.0 million in 2022, then surged by 32.73% to $8.0 million in 2023, then crashed by 75.1% to $2.0 million in 2024, then crashed by 1502.17% to -$27.8 million in 2025.
  • Business Quant data shows Change in Receivables for TVTX at -$27.8 million in Q4 2025, $44.2 million in Q3 2025, and $4.3 million in Q2 2025.